Alpha-Glycosyl Isoquercetin (AGIQ) is a modified form of quercetin designed to improve its bioavailability. Scientific evidence supports its use in reducing some chemotherapy-induced side effects, particularly chemotherapy-induced venous thromboembolism (VTE). AGIQ has been studied in clinical settings, most notably in a phase II randomized trial (the Quercegen study, 2018) in patients with cancer undergoing chemotherapy. This study demonstrated that AGIQ supplementation reduced the incidence of VTE compared to placebo. The proposed mechanism involves AGIQ’s antioxidant, anti-inflammatory, and antiplatelet properties, which may mitigate the hypercoagulable state induced by certain chemotherapies.

Other limited data suggest that quercetin and its derivatives, including AGIQ, may help alleviate additional chemotherapy side effects such as fatigue and mucositis, but robust clinical trials are lacking for these outcomes. Most evidence centers on VTE prevention, and the data is not yet strong enough for widespread clinical adoption, though it is promising. Professional guidelines do not yet recommend AGIQ routinely, but it is sometimes used adjunctively in clinical trials.

In summary, there is scientific—though still emerging—evidence supporting the use of Alpha-Glycosyl Isoquercetin for specific chemotherapy-induced side effects, especially VTE, with moderate-quality clinical studies providing the basis for its use.